Literature DB >> 22176701

Metabolic syndrome in antipsychotic naïve patients diagnosed with schizophrenia.

Sandeep Grover1, Naresh Nebhinani, Subho Chakrabarti, Preeti Parakh, Deepak Ghormode.   

Abstract

AIM: The article aims to study the prevalence of metabolic syndrome (MS) and subthreshold MS in antipsychotic naïve patients with schizophrenia.
MATERIALS AND METHODS: Forty-six antipsychotic naïve patients diagnosed with schizophrenia were evaluated for the presence of metabolic abnormalities using International Diabetes Federation and modified National Cholesterol Education Program-Third Adult Treatment Panel criteria.
RESULTS: Five patients (10.86%) fulfilled International Diabetes Federation criteria for MS and six patients (13.04%) met modified National Cholesterol Education Program-Third Adult Treatment Panel criteria for MS. Additionally, 14 (30.43%) more patients fulfilled 2 out of the 5 criteria for MS and another 19 (41.3%) fulfilled 1 criterion for MS. Of the 19 patients who fulfilled one criterion for MS, 18 had an abnormality other than increase in waist circumference.
CONCLUSION: Findings of the present study suggest that although only few antipsychotic naïve patients diagnosed with schizophrenia have MS, a significantly large proportion of patients have subsyndromal MS. Awareness of this in clinicians can have implications in the selection of antipsychotic medication.
© 2011 Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22176701     DOI: 10.1111/j.1751-7893.2011.00321.x

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  7 in total

1.  Correlates of Metabolic Syndrome in Patients with Schizophrenia: An Exploratory Study.

Authors:  Naresh Nebhinani; Swapnil Tripathi; Navratan Suthar; Vrinda Pareek; Priyanka Purohit; Praveen Sharma
Journal:  Indian J Clin Biochem       Date:  2020-07-06

2.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

3.  Metabolic syndrome in schizophrenia: Differences between antipsychotic-naïve and treated patients.

Authors:  Rakesh K Chadda; Prashanth Ramshankar; Koushik S Deb; Mamta Sood
Journal:  J Pharmacol Pharmacother       Date:  2013-07

4.  Cardiac risk factors and metabolic syndrome in patients with schizophrenia admitted to a general hospital psychiatric unit.

Authors:  Sandeep Grover; Naresh Nebhinani; Subho Chakrabarti; Ajit Avasthi; Debasish Basu; Parmanand Kulhara; Surendra Kumar Mattoo; Savita Malhotra
Journal:  Indian J Psychiatry       Date:  2014-10       Impact factor: 1.759

Review 5.  The Obesity-Impulsivity Axis: Potential Metabolic Interventions in Chronic Psychiatric Patients.

Authors:  Adonis Sfera; Carolina Osorio; Luzmin Acosta Inderias; Victoria Parker; Amy I Price; Michael Cummings
Journal:  Front Psychiatry       Date:  2017-02-13       Impact factor: 4.157

6.  Metabolic Syndrome among Schizophrenic Patients: A Comparative Cross-Sectional Study in the Middle Belt of Ghana.

Authors:  Angela Owusu-Ansah; Anto Berko Panyin; Christian Obirikorang; Christian Agyare; Emmanuel Acheampong; Simon Kwofie; Enoch Odame Anto; Emmanuella Nsenbah Batu
Journal:  Schizophr Res Treatment       Date:  2018-06-28

Review 7.  Metabolic syndrome in schizophrenia.

Authors:  Nidhi Malhotra; Sandeep Grover; Subho Chakrabarti; Parmanand Kulhara
Journal:  Indian J Psychol Med       Date:  2013-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.